DrugPatentWatch Database Preview
RETIN-A Drug Profile
see a sample report or, see our see our flat-rate plans
Which patents cover Retin-a, and when can generic versions of Retin-a launch?
The generic ingredient in RETIN-A is tretinoin. There are twenty-four drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the tretinoin profile page.
Summary for RETIN-A
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 7 |
| Suppliers / Packagers: | 5 |
| Bulk Api Vendors: | 99 |
| Patent Applications: | 4,426 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | RETIN-A at DailyMed |
Medical Subject Heading (MeSH) Categories for RETIN-A
Synonyms for RETIN-A
| .beta.-all-trans-Retinoic acid |
| .beta.-Retinoic acid |
| (11Z)-retinoic acid |
| (2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid |
| (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid |
| (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetr aenoic acid |
| (2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoic acid |
| (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid |
| (2E,4E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraenoic acid |
| (4E,6E,8E)-9-(2,6,6-Trimethyl-1-cyclohexenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid |
| (5E)-Retinoic acid |
| (9Z,13Z)-Retinoic acid |
| (all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid |
| [3H]RA |
| [3H]Retinoic acid |
| [3H]tretinoin |
| [3H]Vitamin A acid |
| [All-E]-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid |
| 02T794 |
| 13497-05-7 (hydrochloride salt) |
| 15-Apo-beta-caroten-15-oic acid |
| 187175-63-9 |
| 1cbr |
| 1n4h |
| 2,4, 6,8-Nonatetranoic acid, 3,7-dimethyl-9-(2,6, 6-trimethyl-1-cyclohexen-1-yl)-, (2E, 4E, 6E, 8E)- |
| 2,4,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)--, (all trans)- |
| 2,4,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)- |
| 2,4,6,8-Nonatetranoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)- |
| 2,4,6,8-Nonatetranoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all trans)- |
| 2,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)- |
| 2,6,8-Nonatetranoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)- |
| 3,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid |
| 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid |
| 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid-, (all trans)- |
| 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2E,4E,6E,8E,-nonatetraenoic acid |
| 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ECL) |
| 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid |
| 3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-all-trans-tetraenoic acid |
| 3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2E,4E,6E,8E-tetraenoic acid |
| 302-79-4 |
| 33998-EP2275420A1 |
| 33998-EP2295055A2 |
| 33998-EP2295416A2 |
| 33998-EP2295426A1 |
| 33998-EP2295427A1 |
| 33998-EP2298748A2 |
| 33998-EP2298764A1 |
| 33998-EP2298765A1 |
| 33998-EP2298768A1 |
| 33998-EP2301928A1 |
| 33998-EP2305642A2 |
| 33998-EP2308833A2 |
| 33998-EP2308861A1 |
| 33998-EP2311453A1 |
| 33998-EP2311808A1 |
| 33998-EP2311829A1 |
| 33998-EP2311840A1 |
| 4759-48-2 |
| 56573-65-0 |
| 5688UTC01R |
| 5914-EP2275412A1 |
| 5914-EP2292576A2 |
| 6-s-trans-retinoic acid |
| 7005-78-9 |
| 9-cis-RA |
| 9-cis-retinoic acid (9cRA) |
| 9-trans-retinoic acid |
| 97950-17-9 |
| A-Acido (Argentina) |
| A-Vitaminsyre |
| A-Vitaminsyre [Denmark] |
| AB00052318_18 |
| AB00052318_19 |
| AB00052318-15 |
| AB00052318-16 |
| AB00052318-17 |
| AB1009361 |
| Aberel |
| Aberela |
| Aberela (TN) |
| Aberela [Norway] |
| AC-6824 |
| AC1L9GWO |
| AC1Q1J2J |
| Acid A Vit (Belgium, Netherlands) |
| Acid, all-trans-Retinoic |
| Acid, beta-all-trans-Retinoic |
| Acid, Retinoic |
| Acid, trans-Retinoic |
| Acid, Vitamin A |
| Acide retinoique (French) (DSL) |
| Acnavit |
| Acnavit [Denmark] |
| ACT00012 |
| AGN 100335 |
| AGN100335 |
| Airol |
| AJ-61307 |
| AK-73126 |
| Aknefug |
| Aknoten |
| AKOS000280845 |
| All Trans Retinoic Acid |
| all trans-Retinoic acid |
| all-(E)-Retinoic acid |
| all-cis-retinoic acid |
| All-trans Retinoic Acid |
| All-trans Retinoic Acid (Tretinoin) |
| all-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic Acid |
| all-trans-b-Retinoic acid |
| all-trans-beta-Retinoic acid |
| all-trans-Retinoate |
| all-trans-Retinoic acid |
| all-trans-retinoic acid (ATRA) |
| all-trans-Tretinoin |
| all-trans-Vitamin A acid |
| all-trans-Vitamin A1 acid |
| Alltrans-retinoic acid |
| AN-9660 |
| ARONIS25153 |
| AT-RA |
| ATRA |
| ATRA; Tretinoin; Vitamin A acid; all-trans-Retinoic acid |
| Atragen |
| Atralin |
| Avita (TN) |
| Avita Gel |
| Avitoin |
| Avitoin [Norway] |
| b-Retinoic acid |
| BC202905 |
| BCPP000036 |
| BDBM31883 |
| beta all trans Retinoic Acid |
| beta-all-trans-Retinoic acid |
| beta-Ra |
| beta-Retinoic acid |
| Betarretin |
| BIDD:GT0483 |
| BIDD:PXR0081 |
| BML2-E05 |
| bmse000562 |
| BP-20401 |
| BPBio1_000082 |
| BR-73126 |
| BRD-K06926592-001-01-7 |
| BRD-K71879491-001-22-6 |
| BRN 2057223 |
| BSPBio_000074 |
| BSPBio_001500 |
| C00777 |
| CAS-302-79-4 |
| CCG-39912 |
| CCRIS 3294 |
| CHEBI:15367 |
| CHEMBL38 |
| cid_444795 |
| Cordes vas |
| Cordes VAS [Germany] |
| CPD000058245 |
| CS-1269 |
| D00094 |
| D02DGU |
| D0A8ND |
| Dermairol |
| DSSTox_CID_1239 |
| DSSTox_GSID_21239 |
| DSSTox_RID_76031 |
| DTXSID7021239 |
| Effederm |
| Effederm [France] |
| EINECS 206-129-0 |
| Epi-aberel |
| EU-0101061 |
| Eudyna |
| GS-3578 |
| GTPL2644 |
| HMS1361K22 |
| HMS1568D16 |
| HMS1791K22 |
| HMS1921D14 |
| HMS1989K22 |
| HMS2089D20 |
| HMS2092N11 |
| HMS2095D16 |
| HMS2236N03 |
| HMS3259E11 |
| HMS3263E04 |
| HMS3402K22 |
| HMS502N05 |
| HSDB 2169 |
| HY-14649 |
| I04-0008 |
| I14-2351 |
| IDI1_000903 |
| IDI1_033970 |
| Isotretinoin Retinoicacid |
| Isotretinoin;(2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid |
| J10054 |
| KB-66303 |
| L000833 |
| LMPR01090019 |
| Lopac0_001061 |
| LP01061 |
| LP091236 |
| LS-1154 |
| MFCD00001551 |
| MLS000028588 |
| MLS001076515 |
| MLS002207234 |
| MLS002222211 |
| MLS002548861 |
| MLS006010222 |
| MolPort-000-883-857 |
| NC00481 |
| NCGC00017280-05 |
| NCGC00017280-06 |
| NCGC00017280-07 |
| NCGC00017280-08 |
| NCGC00017280-09 |
| NCGC00017280-10 |
| NCGC00017280-12 |
| NCGC00017280-15 |
| NCGC00017280-16 |
| NCGC00017280-17 |
| NCGC00017280-18 |
| NCGC00017280-19 |
| NCGC00017280-20 |
| NCGC00017280-23 |
| NCGC00021808-04 |
| NCGC00021808-05 |
| NCGC00021808-06 |
| NCGC00021808-07 |
| NCGC00021808-09 |
| NCGC00021808-11 |
| NCGC00021808-14 |
| NCGC00021808-15 |
| NCGC00254179-01 |
| NCGC00259879-01 |
| NCGC00261746-01 |
| Nexret |
| NSC 122758 |
| NSC-122758 |
| NSC-759631 |
| NSC122758 |
| NSC759631 |
| Opera_ID_1055 |
| OR007900 |
| PDT-002-002 |
| Pharmakon1600-01502016 |
| Potassium Salt, Tretinoin |
| Prestwick_424 |
| Prestwick2_000257 |
| Prestwick3_000257 |
| PubChem16466 |
| Q-200610 |
| QCR-120 |
| R 2625 |
| R0064 |
| REA |
| Refissa |
| Renova |
| Renova (TN) |
| Retacnyl |
| Retin A |
| Retin A (TN) |
| Retin-A (TN) |
| Retin-A Micro |
| Retinoate |
| Retinoic acid |
| Retinoic acid all trans |
| Retinoic acid, >=98% (HPLC), powder |
| Retinoic acid, 98% 250mg |
| RETINOIC ACID, ALL TRANS |
| Retinoic acid, all-trans- |
| Retinoic acid, all-trans- (8CI) |
| Retinoic acid, all-trans-(8CI) |
| Retinoic acid, cis- |
| Retinova |
| Retionic acid |
| Retisol-A |
| Ro 1-5488 |
| RP17637 |
| S-1635 |
| s1653 |
| Salt, Tretinoin Potassium |
| Salt, Tretinoin Sodium |
| Salt, Tretinoin Zinc |
| SAM002264647 |
| SBB065722 |
| SBI-0051031.P003 |
| SC-16932 |
| SCHEMBL19091395 |
| SCHEMBL3145 |
| SHGAZHPCJJPHSC-YCNIQYBTSA-N |
| SMR000058245 |
| Sodium Salt, Tretinoin |
| SPECTRUM1502016 |
| Spectrum5_001746 |
| Spectrum5_001933 |
| SR-01000000239 |
| SR-01000000239-14 |
| SR-01000000239-6 |
| ST057075 |
| ST2407905 |
| Stieva-A |
| Stieva-A (TN) |
| TNP00194 |
| Tox21_110812 |
| Tox21_110812_1 |
| Tox21_202330 |
| Tox21_300305 |
| Tox21_501061 |
| trans Retinoic Acid |
| trans-Retinoic acid |
| trans-Retinoic acid|||Retinoid analogues |
| Trans-Retinoicacid |
| Tretin M |
| tretinoin |
| Tretinoin - Retinoic Acid |
| Tretinoin (JAN/USP/INN) |
| Tretinoin (Retinoic acid) |
| Tretinoin (TN) |
| Tretinoin [USAN:INN:BAN] |
| Tretinoin [USAN:USP:INN:BAN] |
| Tretinoin 0.1% cream or placebo |
| tretinoin liposome |
| tretinoin potassium |
| Tretinoin Potassium Salt |
| tretinoin sodium |
| Tretinoin Sodium Salt |
| Tretinoin Zinc Salt |
| Tretinoin, all-trans- |
| Tretinoin, European Pharmacopoeia (EP) Reference Standard |
| Tretinoin, pharmaceutical secondary standard; traceable to USP and PhEur |
| Tretinoin, United States Pharmacopeia (USP) Reference Standard |
| Tretinoin/All-Trans Retinoic Acid |
| Tretinoina |
| Tretinoina [INN-Spanish] |
| Tretinoine |
| tretinoine (French) (EINECS) |
| Tretinoine [INN-French] |
| Tretinoino |
| Tretinoino [INN-Spanish] |
| Tretinoinum |
| Tretinoinum [INN-Latin] |
| TRETINON |
| Tri-Luma |
| UNII-5688UTC01R |
| UPCMLD-DP097 |
| Vesanoid |
| Vesanoid (TN) |
| Vesanoid (TN) (Roche) |
| Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Tretinoin |
| Vesnaroid |
| Vitamin A acid |
| Vitamin A acid, all-trans- |
| Vitamin a acid, trans- |
| Vitamin A1 acid, all-trans- |
| WLN: L6UTJ A1 B1U1Y1 & U2U1Y1 & U1VQ C1 C1 |
| WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U1VQ C1 C1 |
| Zinc Salt, Tretinoin |
| ZINC12358651 |
US Patents and Regulatory Information for RETIN-A
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valeant Bermuda | RETIN-A | tretinoin | CREAM;TOPICAL | 019049-001 | Sep 16, 1988 | AB | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
| Valeant Intl | RETIN-A | tretinoin | SWAB;TOPICAL | 016921-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Valeant Intl | RETIN-A | tretinoin | GEL;TOPICAL | 017955-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
| Valeant Intl | RETIN-A MICRO | tretinoin | GEL;TOPICAL | 020475-002 | May 10, 2002 | AB | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Expired US Patents for RETIN-A
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Valeant Bermuda | RETIN-A | tretinoin | CREAM;TOPICAL | 017522-001 | Approved Prior to Jan 1, 1982 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Valeant Pharms North | RETIN-A | tretinoin | CREAM;TOPICAL | 017340-001 | Approved Prior to Jan 1, 1982 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Valeant Intl | RETIN-A | tretinoin | GEL;TOPICAL | 017955-001 | Approved Prior to Jan 1, 1982 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Valeant Bermuda | RETIN-A | tretinoin | CREAM;TOPICAL | 019049-001 | Sep 16, 1988 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for RETIN-A
| Drugname | Dosage | Strength | RLD | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Gel | 0.04% | ➤ Subscribe | 2010-12-20 |
| ➤ Subscribe | Gel | 0.1% | ➤ Subscribe | 2010-07-08 |
see a sample report or, see our see our flat-rate plans
